Malignant melanoma of the sinonasal cavity is an uncommon disease, and therefore a limited amount of data exists regarding its optimal treatment. The course of the disease is highly variable. Individual survival is also highly variable, but the overall prognosis is poor; probably because patients generally present at a late stage and because the disease has a proclivity for distant dissemination. We describe 2 recent cases of primary malignant melanoma of the sinonasal mucosa, and we review the literature.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions.
Am Soc Clin Oncol Educ Book
January 2025
Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Cell-based therapies have become integral to the routine clinical management of hematologic malignancies. Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in immunogenic solid tumors, such as melanoma. However, in the GI field, evidence supporting the clinical success of cell-based therapies is still awaited.
View Article and Find Full Text PDFMusician's Experience After Breast Cancer Treatment: Defining Musical Toxicity and its Frequency.
JCO Oncol Pract
January 2025
Mayo Clinic, Department of Internal Medicine, Division of Oncology, Rochester, MN.
Purpose: Over 50% of households in the United States have at least one musician-many musicians are also breast cancer survivors. This group has not been well studied, and given the level of fine sensory-motor skill required for musicianship, we hypothesized that musicians experience unique manifestations of breast cancer treatment toxicities.
Methods: A nine-item Musical Toxicity Questionnaire (MTQ) was distributed to patients who had consented to participate in the Mayo Clinic Breast Cancer Registry.
Mitochondrial respiratory complex III sustains IL-10 production in activated macrophages and promotes tumor-mediated immune evasion.
Sci Adv
January 2025
School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
The cytokine interleukin-10 (IL-10) limits the immune response and promotes resolution of acute inflammation. Because of its immunosuppressive effects, IL-10 up-regulation is a common feature of tumor progression and metastasis. Recently, IL-10 regulation has been shown to depend on mitochondria and redox-sensitive signals.
View Article and Find Full Text PDFResearch Advances in Terahertz Technology for Skin Detection.
Photobiomodul Photomed Laser Surg
January 2025
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
With the continuous development of Terahertz technology and its high sensitivity to water, Terahertz technology has been widely applied in various research areas within the field of biomedicine, such as research onskin wounds and burns, demonstrating numerous advantages and potential. The aim of this study is to summarize and conclude the current research status of Terahertz radiation in skin wounds, burns, and melanoma. Additionally, it seeks toreveal the development status of Terahertz in skin wound models and analyze the short comings of Terahertz in detecting such models at the present stage.
View Article and Find Full Text PDFPTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers.
J Exp Med
March 2025
Institute of Cancer Research, Shenzhen Bay Laboratory , Shenzhen, China.
BRAF mutations drive initiation and progression of various tumors. While BRAF inhibitors are effective in BRAF-mutant melanoma patients, intrinsic or acquired resistance to these therapies is common. Here, we identify non-receptor-type protein tyrosine phosphatase 23 (PTPN23) as an alternative effective target in BRAF-mutant cancer cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!